Literature DB >> 33222091

Talc pleurodesis in malignant pleural effusion: a systematic review and meta-analysis.

Eleftherios T Beltsios1,2, Georgios Mavrovounis3, Antonis Adamou3,4, Nikolaos Panagiotopoulos5.   

Abstract

OBJECTIVE: Malignant pleural effusion is a severe and common complication in patients with primary or metastatic malignancies of the pleura. Although talc pleurodesis is widely used for managing malignant pleural effusions, there is still controversy in the literature regarding its superiority compared to other approaches. We conducted this meta-analysis to further investigate its efficacy compared to alternative interventions.
METHODS: We systematically reviewed the PubMed, Cochrane, and Scopus databases to identify studies that fulfilled our inclusion criteria. Study quality was evaluated using validated tools and the pooled Risk Ratio (RR) and confidence interval (CI) were calculated. We performed sensitivity analyses based on the meta-analysis method and type of study.
RESULTS: Twenty-four studies were included in the current systematic review meta-analysis. Talc pleurodesis was associated with statistically significant higher successful pleurodesis rates when compared with all controls [RR (95% CI) 1.15 (1.00, 1.31); Pz = 0.04], only chemical controls [RR (95% CI) 1.26 (1.13, 1.40); Pz < 0.0001], and bleomycin [RR (95% CI) 1.22 (1.05, 1.42); Pz = 0.008]. The comparison between talc pleurodesis and controls at the > 1-month follow-up time point favored talc pleurodesis [RR (95% CI): 1.62 (1.15, 2.27); Pz = 0.005]. Finally, talc poudrage was associated with a statistically significant higher successful pleurodesis rate when compared with all controls. Sensitivity analyses verified the robustness of our results.
CONCLUSION: Talc pleurodesis is an effective MPE management approach presenting borderline statistically significant superiority compared to control methods especially compared to bleomycin as well as when pleurodesis success is evaluated later than 1 month postoperatively.

Entities:  

Keywords:  Chemical pleurodesis; Ipcs; Malignant pleural effusions; Meta-analysis; Talc pleurodesis

Year:  2020        PMID: 33222091     DOI: 10.1007/s11748-020-01549-2

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  44 in total

1.  Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010.

Authors:  Mark E Roberts; Edmund Neville; Richard G Berrisford; George Antunes; Nabeel J Ali
Journal:  Thorax       Date:  2010-08       Impact factor: 9.139

2.  Asymptomatic malignant pleural effusion: to observe or to manage.

Authors:  Sevak Keshishyan; Kassem Harris
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 3.  Malignancies metastatic to the pleura.

Authors:  R A Matthay; L Coppage; C Shaw; A E Filderman
Journal:  Invest Radiol       Date:  1990-05       Impact factor: 6.016

4.  Prognosis of Cancer with Synchronous or Metachronous Malignant Pleural Effusion.

Authors:  José M Porcel; Cristina Solé; Antonieta Salud; Silvia Bielsa
Journal:  Lung       Date:  2017-09-12       Impact factor: 2.584

5.  Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses.

Authors:  José M Porcel; Aureli Esquerda; Manuel Vives; Silvia Bielsa
Journal:  Arch Bronconeumol       Date:  2013-12-20       Impact factor: 4.872

6.  Comparison of modified Borg scale and visual analog scale dyspnea scores in predicting re-intervention after drainage of malignant pleural effusion.

Authors:  Rogier C Boshuizen; Andrew D Vincent; Michel M van den Heuvel
Journal:  Support Care Cancer       Date:  2013-07-11       Impact factor: 3.603

Review 7.  ERS/EACTS statement on the management of malignant pleural effusions.

Authors:  Anna C Bibby; Patrick Dorn; Ioannis Psallidas; Jose M Porcel; Julius Janssen; Marios Froudarakis; Dragan Subotic; Phillippe Astoul; Peter Licht; Ralph Schmid; Arnaud Scherpereel; Najib M Rahman; Nick A Maskell; Giuseppe Cardillo
Journal:  Eur J Cardiothorac Surg       Date:  2019-01-01       Impact factor: 4.191

8.  The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial.

Authors:  Rahul Bhatnagar; Brennan C Kahan; Anna J Morley; Emma K Keenan; Robert F Miller; Najib M Rahman; Nick A Maskell
Journal:  Trials       Date:  2015-02-12       Impact factor: 2.279

9.  Talc pleurodesis versus indwelling pleural catheter among patients with malignant pleural effusion: a meta-analysis of randomized controlled trials.

Authors:  Li Wang; Huan Deng; Xinling Chen; Can Li; Fengming Yi; Yiping Wei; Wenxiong Zhang
Journal:  World J Surg Oncol       Date:  2020-07-23       Impact factor: 2.754

10.  Identifying Human Genome-Wide CNV, LOH and UPD by Targeted Sequencing of Selected Regions.

Authors:  Yu Wang; Wei Li; Yingying Xia; Chongzhi Wang; Y Tom Tang; Wenying Guo; Jinliang Li; Xia Zhao; Yepeng Sun; Juan Hu; Hefu Zhen; Xiandong Zhang; Chao Chen; Yujian Shi; Lin Li; Hongzhi Cao; Hongli Du; Jian Li
Journal:  PLoS One       Date:  2015-04-28       Impact factor: 3.240

View more
  2 in total

Review 1.  Treating Recurrent Pleural Disease: A Review of Indications and Technique for Chemical Pleurodesis for the Interventional Radiologist.

Authors:  Surbhi B Trivedi; Matthew Niemeyer
Journal:  Semin Intervent Radiol       Date:  2022-08-31       Impact factor: 1.780

2.  Pleural Resident Macrophages and Pleural IRA B Cells Promote Efficient Immunity Against Pneumonia by Inducing Early Pleural Space Inflammation.

Authors:  Alan Bénard; Malgorzata J Podolska; Franziska Czubayko; Isabella Kutschick; Bettina Klösch; Anne Jacobsen; Elisabeth Naschberger; Maximilian Brunner; Christian Krautz; Denis I Trufa; Horia Sirbu; Roland Lang; Robert Grützmann; Georg F Weber
Journal:  Front Immunol       Date:  2022-04-14       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.